Adjuvant dose-dense chemotherapy is not associated with improved invasive event-free interval in early-stage node-negative HER2-negative breast cancer
The Oncologist · 20.11.2026
DOI: 10.1093/oncolo/oyag450 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 20.11.2026. Verfasst von Jonathan Shpigelman und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Adjuvant dose-dense (DD) chemotherapy improves outcomes in early-stage, node-positive breast cancer and is commonly extrapolated to node-negative disease despite limited evidence and increased toxicity. Whether DD chemotherapy confers benefit in this lower risk population remains unclear. Patients and Methods Women aged ≥18 years with T1–T2, node-negative, HER2-negative breast cancer who underwent definitive surgical resection and received adjuvant DD or non-DD chemotherapy were retrospectively identified. Invasive breast cancer-free interval (IBCFI) and overall survival (OS) were compared between treatment groups using log-rank tests. Hazard ratios (HRs) for invasive breast cancer events and all-cause mortality were estimated using both inverse probability of treatment–weighted (IPTW) and Firth-penalized Cox regression.
Results
Among 169 patients diagnosed between 1999 and 2017, 58 received DD chemotherapy. Over a median follow-up of 13.8 years, 22 patients experienced an invasive event and 28 died, including 6 breast cancer-related deaths. DD chemotherapy was not associated with invasive events (IPTW: HR 0.88, 95% CI 0.32–2.42; Firth: HR 0.96, 95% CI 0.34–2.67) or all-cause mortality (IPTW: HR 1.40, 95% CI 0.58–3.40; Firth: HR 1.88, 95% CI 0.78–4.56). In Firth-penalized Cox regression, lymphovascular invasion was strongly associated with increased hazard of invasive events (HR 4.75, 95% CI 1.62–13.97), while T2 stage trended toward increased risk (HR 2.45, 95% CI 0.92–6.52).
Conclusion
In patients with T1–T2, node-negative, HER2-negative breast cancer, DD adjuvant chemotherapy was not associated with a lower hazard of invasive events or all-cause mortality. Prospective studies are needed to clarify whether selected higher-risk subgroups, including patients with lymphovascular invasion and T2 tumors, benefit from chemotherapy schedule intensification.
Zitieren
APA
Shpigelman, J., Alsebai, T., Koirala, S., Buhnerkempe, M., Nimavat, A., PhD, K. R., Cossyleon, R., & Rao, K. (2026). Adjuvant dose-dense chemotherapy is not associated with improved invasive event-free interval in early-stage node-negative HER2-negative breast cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag450
Vancouver
Shpigelman J, Alsebai T, Koirala S, Buhnerkempe M, Nimavat A, PhD KR, et al. Adjuvant dose-dense chemotherapy is not associated with improved invasive event-free interval in early-stage node-negative HER2-negative breast cancer. The Oncologist. 2026. doi:10.1093/oncolo/oyag450
BibTeX
@article{Shpigelman2026,
author = {Shpigelman, Jonathan and Alsebai, Tasnem and Koirala, Sajan and Buhnerkempe, Michael and Nimavat, Aum and PhD, Kathy Robinson and Cossyleon, Ricardo and Rao, Krishna},
title = {Adjuvant dose-dense chemotherapy is not associated with improved invasive event-free interval in early-stage node-negative HER2-negative breast cancer},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag450}
}
EUVIMED